Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma

NCT01007448 is registered in ClinicalTrials.gov with Bausch Health Americas, Inc. as lead sponsor.

NCT NCT01007448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01007448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma
Lead sponsor
Bausch Health Americas, Inc.
Phase
Phase 4
Overall status
Completed
Start date
January 6, 2010
Completion date
February 20, 2014
Enrollment
59 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

refractory cutaneous t-cell lymphoma